Lacunar Stroke: Single Antiplatelet Therapy Is the Standard for Long-Term Secondary Prevention
For patients with lacunar (small-vessel) ischemic stroke, single antiplatelet therapy—not dual antiplatelet therapy—should be used for long-term secondary prevention beyond the acute period. 1, 2
Acute Phase (First 21–30 Days): Consider Short-Term Dual Antiplatelet Therapy Only If Specific Criteria Are Met
Eligibility for Short-Term DAPT
- Dual antiplatelet therapy (aspirin + clopidogrel) for 21 days is recommended only if the lacunar stroke is minor (NIHSS ≤ 3) AND the patient presents within 24 hours of symptom onset. 1, 3
- The 2021 AHA/ASA guideline explicitly states that the diagnosis must be confirmed by imaging as a non-lacunar embolic ischemic stroke for DAPT eligibility—meaning that typical lacunar strokes (small subcortical infarcts) do not automatically qualify for DAPT unless they meet the minor stroke criteria above. 1
- If the lacunar stroke is moderate-to-severe (NIHSS > 3) or presentation is beyond 24–72 hours, proceed directly to single antiplatelet therapy. 1, 3
DAPT Protocol (If Eligible)
- Loading dose (Day 1): clopidogrel 300 mg + aspirin 160–325 mg within 12–24 hours of symptom onset, after intracranial hemorrhage is excluded on CT/MRI. 1, 3
- Maintenance (Days 2–21): clopidogrel 75 mg daily + aspirin 75–100 mg daily for exactly 21 days. 1, 3
- After Day 21, transition to single antiplatelet therapy indefinitely. 1, 3
Long-Term Secondary Prevention (Beyond 21–30 Days): Single Antiplatelet Therapy Is the Evidence-Based Standard
Why Single Antiplatelet Therapy for Lacunar Stroke?
- A pooled analysis of 17 randomized trials (42,234 participants) specifically examining lacunar stroke found that any single antiplatelet agent reduced recurrent stroke by 23% compared with placebo (RR 0.77,95% CI 0.62–0.97). 2
- The same analysis found that dual antiplatelet therapy did not confer clear benefit over monotherapy for lacunar stroke (any stroke RR 0.83,95% CI 0.68–1.00; ischemic stroke RR 0.80,95% CI 0.62–1.02). 2
- Long-term DAPT (beyond 30 days) in lacunar stroke patients significantly increases major bleeding risk (RR 2.42,95% CI 1.37–4.30) without reducing recurrent stroke (RR 0.89,95% CI 0.79–1.02). 1
- The SPS3 trial, which specifically enrolled lacunar stroke patients, showed no benefit of long-duration DAPT (aspirin + clopidogrel) compared with aspirin alone, but major hemorrhages were significantly higher in the DAPT group. 1
First-Line Single Antiplatelet Options
- Aspirin 75–100 mg daily is the first-line recommendation for long-term maintenance. 1, 3
- Clopidogrel 75 mg daily is an equally effective alternative, particularly preferred in patients with diabetes, aspirin intolerance, or peripheral arterial disease. 1, 3
- Aspirin 25 mg + extended-release dipyridamole 200 mg twice daily is another acceptable regimen. 1, 3
Critical Pitfalls to Avoid
- Do not continue dual antiplatelet therapy beyond 21–30 days in lacunar stroke patients without a separate cardiac indication (e.g., recent coronary stent), as bleeding risk outweighs any potential benefit. 1, 2
- Do not assume that all lacunar strokes qualify for short-term DAPT; the patient must meet the specific criteria of minor stroke (NIHSS ≤ 3) and early presentation (≤ 24 hours). 1
- Do not withhold single antiplatelet therapy in lacunar stroke patients with cerebral microbleeds on MRI, as current data does not support this practice. 4
Evidence Quality
- The recommendation for single antiplatelet therapy in lacunar stroke is supported by high-quality evidence (pooled analysis of 17 RCTs with 42,234 participants). 2
- The recommendation against long-term DAPT in lacunar stroke is supported by the SPS3 trial and meta-analyses showing increased bleeding without benefit. 1, 2
- The 2021 AHA/ASA guideline provides a Class I, Level A recommendation for short-term DAPT in minor stroke/high-risk TIA, but this does not automatically apply to all lacunar strokes. 1